

AMOÉBA announces the possible use of its substance for the treatment of one of the pathogens of field crops, rust

Chassieu, July 1, 2019 - AMOÉBA (FR0011051598 - AMEBA), producer of a biological biocide, still in the testing phase, capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, announces an efficacy of more than 85% of its amoeba lysate *Willaertia magna* C2c Maky in planta against rust. Rust is a group of diseases that are particularly damaging to field crops (soybeans, wheat, etc.).

Amoéba thus broadens its spectrum of action in biocontrol application by demonstrating an in planta efficacy of more than 85% against bean rust used as a rust model. The tests were carried out by an independent expert company, according to a standard protocol. Rust is caused by the fungus *Uromyces fabae*, a pathogen very different from the other germs (downy mildew of grapevine and late blight of potato) on which the lysed amoeba has already demonstrated its action in planta.

To date, there is no biocontrol product in the world for the treatment of soybean rust or cereal rusts. The field crop market is by far the most important fungicide market. For information, the fungicide market for cereals in Europe is estimated at \$2 billion dollars and \$1 billion for the treatment of soybean rust alone in Brazil.

This new demonstration of efficacy against one of the most fought diseases in the world confirms the strategic dimension of biocontrol in the development of the amoeba application portfolio.

"These new results show us that the product has a broad spectrum of action, but the extent of it has yet to be defined. Using our amoeba lysed in field crops could considerably expand our range of treatments. The challenge for us is now to make the most of these advances as quickly as possible with external partners," says Fabrice PLASSON, Chairman and CEO of Amoéba.



About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations.



The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE

General Manager

+33 (0)4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Investors Relations

Grégory BOSSON

Agence Calyptus

+33(0)1 53 65 37 90

gregory.bosson@calyptus.net

Medias relations

Constance LOZET

Agence Ekno

+33(0)7 78 41 19 70

constance.lozet@ekno.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 25, 2019 under number D19-0383 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.